Zika virus infection elicits autoantibodies to C1q

Takaaki Koma1,2,11, Veljko Veljkovic3, Danielle E. Anderson4, Lin-Fa Wang6, Shannan L. Rossi1,2, Chao Shan4, Pei-Yong Shi5,6,7,8, David W. Beasley9, Natalya Bukreyeva1,2, Jeanon N. Smith1,2, Steven Hallam1,2, Cheng Huang1,2, Veronika von Messling4,10 & Slobodan Paessler1,2

Zika virus (ZIKV), a member of the family Flaviviridae, is the causative agent of Zika fever. Most cases are asymptomatic or patients develop mild symptoms with a maculopapular rash1. However, due to the rapid increase of ZIKV infections causing fetal deaths and more than 4,000 microcephaly cases and neurological disorders in affected areas, the World Health Organization (WHO) declared a public health emergency of international concern on February 1, 20162. Although ZIKV was discovered nearly 70 years ago, data on the interaction of this virus with host targets is lacking and viral pathogenesis is still poorly understood. Currently, there is no prophylactic vaccine or effective therapy for Zika fever available.

To determine if there are host proteins with a pattern similar to the ZIKV envelope (E) glycoprotein, we analyzed this protein with informational spectrum method (ISM). Our analysis identified C1q, a member of the complement complex, as a host protein with common informational features, suggesting some similarity in biological properties. In addition to its role as the initial component of the classical complement cascade, C1q is known to be not only involved in innate immunity but also in homeostasis, angiogenesis, apoptosis, autoimmunity and synaptic organization3–5. Here, we demonstrate that ZIKV infection elicited antibodies specific to C1q in mice and non-human primates (NHP), which may contribute to the observed neurological complications.

Results

Human C1q shares spectral features with ZIKV but not West Nile virus E protein. The consensus informational spectrum of 39 ZIKV E proteins (Fig. 1A and Supplementary dataset 1) was characterized, identifying a conserved dominant peak at the frequency $F = 0.338$. A dominant peak at this frequency was also found in the cross-spectrum between ZIKV E protein and human C1q (Fig. 1B). In contrast, the E protein of West Nile
virus (WNV), another flavivirus, did not share spectral features with human C1q in the ISM analysis (Fig. 1C). Similar results were observed with mouse C1q and E proteins of ZIKV and WNV (Fig. 1D,E). This indicates that ZIKV E protein may specifically modulate the function of the human complement system \textit{via} induction of E protein-specific antibodies that also cross-react with C1q.
ZIKV infection induces C1q-specific antibodies. To assess if the similar profiles observed in ISM analysis translate into antibody cross-reactivity, we quantified anti-C1q-specific antibodies using ELISA system.

Immunodeficient A129 mice have been known to develop a disease after ZIKV inoculation in association with viremia, while immunocompetent CD-1 mice were not susceptible for ZIKV infection unless inoculated intracranially. Therefore, to measure the immune responses we used both mouse models in our study. Serum samples were obtained from A129 mice lacking the type I interferon receptor as well as immunocompetent CD-1 mice on the indicated days after infection with the Cambodian ZIKV strain FSS13025. Seven out of 8 A129 mice displayed increased anti-C1q antibodies titers at 57 and 76 days post-infection (dpi) (Fig. 2A). Furthermore, a statistically significant increase in C1q-specific antibodies was observed in all five CD-1 mice at 15 dpi and the titer remained elevated in 4 animals until 30 dpi (Fig. 2B). Comparison of pre- and post-infection anti-C1q antibody levels in A129 mice revealed a significant increase at 28 dpi (Fig. 2C). To validate our findings in an animal model that is physiologically closer to humans, the presence of C1q-specific antibodies in serum samples from cynomolgus macaques infected with the Polynesian ZIKV strain H/PF/2013 strain was investigated using a macaque-specific ELISA kit. The analysis revealed an increase in C1q antibody levels in three out of the six animals at 11 dpi, when the animals were euthanized (Fig. 2D). Collectively, our results experimentally demonstrate that ZIKV infection can induce measurable levels of C1q cross-reactive antibodies not only in immunodeficient mice but also in immunocompetent mice and NHPs.

As ISM analysis demonstrated that the similarity with C1q is not shared with WNV E protein, we also quantified anti-C1q antibody response in WNV-infected immunocompetent BALB/c mice at 21 dpi. As predicted, even though all animals had neutralizing antibody titers against WNV of 1:320 or above, no increase in anti-C1q antibodies was detected (Fig. 2E).

C1q shares spectral features with the E protein of another flavivirus, Yellow fever virus. To explore if other flavivirus E proteins have similar properties to ZIKV, the E proteins of Dengue virus type 1 (DENV-1), Yellow fever virus (YFV) and tick-borne encephalitis virus (TBEV) were also analyzed by ISM method (Fig. 3). The DENV-1 E protein and C1q, and TBEV E protein and C1q are characterized by relatively low peak frequency F3. The DENV-1 E protein and C1q, and TBEV E protein and C1q are characterized by relatively low peak frequency F3.

In this study, we demonstrated that animals infected with ZIKV develop antibodies against C1q, leading to speculation that these antibodies might contribute to ZIKV-associated complications such as microcephaly, thrombocytopenia and/or Guillain-Barré syndrome (GBS).

In the present study, we found informational similarities between C1q and the E protein of ZIKV using ISM, suggesting some biological similarity between these proteins. This similarity was not demonstrated for E protein from WNV. In accordance, we detected the elevated antibodies specific to C1q from almost all animals infected with ZIKV but not WNV.

Auto-antibodies to C1q have been frequently detected in patients with autoimmune diseases, for examples, hypocomplementemic urticarial vasculitis (100%), Felty's syndrome (76%), Lupus nephritis (63%) and systemic Lupus erythematosus (SLE) (33%). Conversely, anti-C1q antibodies can only be detected in 5–10% of “healthy” individuals and the etiology of their induction is unknown. The levels of anti-C1q antibodies often show a significant converse correlation with the level of C1q and C3. Although the levels of C1q and C3 have not been measured in this study, the amount of C1q may decrease in the presence of high titers of anti-C1q antibodies titers. C1q and C3 are known to be involved not only in innate immunity but also brain development. Mice deficient in C1q or C3 have impaired synapse elimination during development, indicating that C1q and C3 are required for normal synaptic pruning. Another study also reported that C1q is required for synapse elimination in the cortical layer, and a case report showed that a girl was born with head circumference <3rd percentile concomitantly with very low levels of C1q due to a mutation in the C1qb gene. Therefore, viral infections that elicit cross-reactive anti-C1q antibodies may not only affect the course of the acute disease, but also impair normal brain development and function long after virus clearance. The proposed molecular mimicry between E protein of ZIKV origin and C1q that was identified using ISM might thus contribute to ZIKV-related microcephaly seen in infected babies or other neurological syndromes.

Recently, it was suggested that one additional important manifestation of ZIKV disease is immune-mediated severe thrombocytopenia. Interestingly, ISM screening of platelets antigens suggested a possible mechanism of ZIKV-associated thrombocytopenia. ISM results showed that the complement component 1 Q subcomponent-binding protein (p32) might be a host protein interacting with ZIKV E protein and/or a potential target for anti-E antibodies through cross reaction (Fig. 1F). Furthermore, recent papers reported ZIKV-related GBS and Sensory Polyneuropathy. Some evidence indicates that the complement components are the cause of GBS. Anti-C1q antibodies or ZIKV infection may activate the complement components and contribute to the development of GBS.

C1q not only plays a role in immunity but also in homeostasis and development. The C1q-mimicking ZIKV E protein might induce autoimmune response against C1q in host. This potential immune response may have implications in the pathogenesis of ZIKV, including development of microcephaly, GBS and thrombocytopenia. More investigations are warranted to confirm these hypotheses. Additionally, it would be important to confirm our data in Zika patients and compare anti-C1q antibody levels between people that were infected and those that have not been infected with ZIKV. In the ISM analysis for other flavivirus E proteins, YFV E protein also shared similar spectral features with both human and murine C1q. Although in present study we did not test the anti-C1q antibody inducibility by YFV infection or vaccine in vivo, future studies are warranted to test the anti-C1q antibody induction after YFV infection. Some cases of neurological diseases such as encephalitis and
Figure 2. Anti-C1q antibody ELISA. (A) A129 mice were infected with ZIKV strain FSS13025 and sacrificed at indicated days. Anti-C1q antibody was measured by ELISA. The cut-off value was 190.0 U/mL (dash line). (B) Serum samples were collected from CD-1 mice infected with ZIKV strain FSS13025 and measured for anti-C1q antibody. The cut-off values were 268.4 U/mL (dash line) for 15 dpi and 205.8 U/mL for 30 dpi. (C) Serum samples were collected at 0 dpi (Pre-infection) and 28 dpi from A129 mice infected with ZIKV strain FSS13025. The dash lines indicate the cut-off value 252.1 U/mL. (D) Serum samples were collected at 0 dpi (Pre-infection) and 11 dpi from cynomolgus macaques (*Macaca fascicularis*) infected with ZIKV strain H/PF/2013. The dash lines indicate the cut-off value 0.272. The data is shown by ELISA OD values since there was no calibration samples in the ELISA kit. (E) Serum samples were collected from BALB/c mice infected with WNV TX AR12–9793 at 21 dpi and measured for anti-C1q antibody. The cut-off values were 178.2 U/mL (dash line). Each dot shows the average values of duplicate wells. The lines between dots indicate that the samples were obtained from same animals. P values were calculated using Mann-Whitney U test (compared with negative control or pre-infection). Each cut-off value was determined by the mean plus 3 SDs of the negative controls (un-infected) or pre-infection.
GBS (suspect) have been reported after Yellow fever vaccination\textsuperscript{21–23}. It would be interesting to study a potential role of YFV-elicited anti-C1q antibody in YFV-associated neurological diseases.

Additionally, as some ZIKV vaccines are entering clinical trials, we believe that it is important to ensure that these vaccines would not induce anti-C1q antibodies, which may mediate autoimmune response in human vaccinees. If the induction of anti-C1q antibodies is identified in vaccinees, safer vaccines should be designed to avoid a risk of eliciting autoimmune responses in healthy humans after vaccination.

**Figure 3.** The ISM analysis of flavivirus E proteins and C1q protein. (A) The cross-spectrum of E protein from DENV-1 (P17763) and human C1q protein. (B) The cross-spectrum of E protein from DENV-1 and mouse C1q protein. (C) The cross-spectrum of E protein from YFV (AAX47570) and human C1q protein. (D) The cross-spectrum of E protein from YFV and mouse C1q protein. (E) The cross-spectrum of E protein from TBEV (AFV41132) and human C1q protein. (F) The cross-spectrum of E protein from TBEV and mouse C1q protein.
Methods

**Informational spectrum method (ISM).** ISM technique has been described in detail previously\(^2\). The ISM is a virtual spectroscopy-based analysis of protein-protein interactions. Amino acid sequences are transformed into signals by assigning numerical values of amino acid in the method\(^2\). These values reflect the electron-ion interaction potential, which determines the electronic properties of amino acid\(^2\). The obtained signal is then decomposed in periodical function by Fourier transformation. The result is displayed by a series of frequencies that correspond to the distribution of structural motifs with defined physico-chemical characteristics. Proteins with overlapping peaks or pattern thus share the biological or biochemical functions\(^2\).

**Viruses and animals.** ZIKV Cambodian strain FSS13025 (10\(^5\)PFU) was intrauterine inoculated into IFN-α/β R\(^{-/-}\) mice (A129 mice) which were bred and maintained in the University of Texas Medical Branch at Galveston and CD-1 mice which were purchased from Charles River Laboratories (Wilmington, MA). Intrapartum administration was previously used to establish ZIKV infection model in mice. All experiments with cynomolgus macaques (Macaca fascicularis) were conducted at SingHealth Experimental Medicine Centre. ZIKV Polynesian strain H/PF/2013 (10\(^5\)PFU) was administered into M. fascicularis by intravenous or subcutaneous routes that mimic mosquito bites. Although different ZIKV strains were used in mice and NHP experiments, they were genetically very similar (amino acid sequence similarity and identity: 99.9% and 99.6%, respectively) and phylogenetically classified into the recent epidemic Asian lineage\(^7\). The experiments with mice and NHP were approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch at Galveston and the Institutional Animal Care and Use Committee of the SingHealth Experimental Medicine Centre, respectively. All methods in this study were performed in accordance with relevant guidelines and regulations. Sera which were previously obtained from WNV-infected animals\(^28\) were used to detect anti-C1q antibodies.

ELISA. To detect anti-C1q specific antibodies, “Mouse Anti C1q Ig’s ELISA kit” (Alpha Diagnostic International, San Antonio, TX) and “Human Anti-Complement 1q antibody ELISA kit” (MyBioSource, San Diego, CA) were used for mouse and NHP, respectively. ELISA was carried out according to the manufacturer’s protocols. For NHP, the human IgG HRP conjugated secondary antibody was substituted with a monkey IgG HRP conjugated secondary antibody.

References

1. Musso, D. & Gubler, D. J. Zika Virus. Clinical microbiology reviews 29, 487–524, https://doi.org/10.1128/CMR.00072-15 (2016).
2. European Centre for Disease Prevention and Control, Public Health Emergency of International Concern (PHEIC) declared for Europe on 20 February 2016, https://ecdc.europa.eu/en/activities/541d1d3d59769552d91f2e0e4869d340.pdf.
3. Troedson, C. The role of C1q in the innate immune response. Bioessays 31, 645–654, https://doi.org/10.1002/bies.20186 (2019).
4. Sharp, T. M. C1q and the innate immune response. Immunobiology 221, 1273–1288, https://doi.org/10.1016/j.imbio.2016.06.002 (2016).
5. Yuzaki, M. The C1q complement family of synaptic organizers: not just complementary. Current opinion in neurobiology 45, 9–15, https://doi.org/10.1016/j.conb.2017.02.002 (2017).
6. Kouser, L. et al. Emerging and Novel Functions of Complement Protein C1q. Frontiers in immunology 6, 317, https://doi.org/10.3389/fimmu.2015.00317 (2015).
7. Ratner, L. et al. Characterization of a Novel Murine Model to Study Zika Virus. The American journal of tropical medicine and hygiene 94, 1362–1369, https://doi.org/10.4269/ajtmh.16-0111 (2016).
8. Duggal, N. K. et al. Differential Neurovirulence of African and Asian Genotype Zika Virus Isolates in Outbred Immunocompetent Mice. The American journal of tropical medicine and hygiene 97, 1410–1417, https://doi.org/10.4269/ajtmh.17-0263 (2017).
9. Kapellen, C. G. Anti-C1q autoantibodies. Autoimmunity reviews 7, 612–615, https://doi.org/10.1016/j.autrev.2008.06.006 (2008).
10. Saadoun, D. et al. Anti-C1q antibodies in hepatitis C virus infection. Clinical and experimental immunology 145, 308–312, https://doi.org/10.1111/j.1365-2249.2006.03153.x (2006).
11. Siegert, C. E. et al. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Annals of the rheumatic diseases 52, 851–856 (1993).
12. Horvath, L. et al. High levels of antibodies against C1q are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clinical and experimental rheumatology 19, 667–672 (2001).
13. Gunnarsson, I. et al. Repeated renal biopsy in proliferative lupus nephritis–predictive role of serum C1q and albuminuria. The journal of rheumatology 29, 693–699 (2002).
14. Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164–1178, https://doi.org/10.1016/j.cell.2007.10.036 (2007).
15. Chen, Y. et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proceedings of the National Academy of Sciences of the United States of America 107, 7975–7980, https://doi.org/10.1073/pnas.0913449107 (2010).
16. Troedson, C. et al. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus 22, 639–643, https://doi.org/10.1177/0961233X13486950 (2013).
17. Sharp, T. M. et al. Zika Virus Infection Associated With Severe Thrombocytopenia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, https://doi.org/10.1093/cid/ciw676 (2017).
18. Chao-Lormeau, V. M. et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531–1539, https://doi.org/10.1016/S0140-6736(16)05652-6 (2016).
19. Marco, T. Medina et al. Zika virus associated with sensory polyneuropathy. Journal of the Neurological Sciences 369, 271–272 (2016).
20. Hafer-Macko, C. E. et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Annals of neurology 39, 625–635, https://doi.org/10.1002/ana.10390512.1996.
21. Putzu, G. A. et al. Immunohistochemical localization of cytokines, C3b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci 174, 16–21 (2000).
22. de Menezes Martins, R., Fernandes Leal Mda, L. & Homma, A. Serious adverse events associated with yellow fever vaccine. Human vaccines & immunotherapeutics 11, 2183–2187, https://doi.org/10.1080/21645515.2015.1022700 (2015).
23. Beira, P. et al. Yellow fever vaccine-associated neurological disease, a suspicious case. BMJ case reports 2017, https://doi.org/10.1136/bcr-2016-218706 (2017).
24. McMahon, A. W. et al. Neurologic disease associated with 17D-204 yellow fever vaccine: a report of 15 cases. Vaccine 25, 1727–1734, https://doi.org/10.1016/j.vaccine.2006.11.027 (2007).
24. Veljkovic, V. et al. *In silico* analysis suggests interaction between Ebola virus and the extracellular matrix. *Frontiers in microbiology* **6**, 135, https://doi.org/10.3389/fmicb.2015.00135 (2015).
25. Veljković, V. The dependence of the fermi energy on the atomic number. *Physics Letters A* **45A**, 41–42, https://doi.org/10.1016/0375-9601(73)90497-0 (1973).
26. Veljković, V. & Slavić, I. Simple General-Model Pseudopotential. *Physical Review Letters* **29**, 105–107, https://doi.org/10.1103/PhysRevLett.29.105 (1972).
27. Tripathi, S. et al. A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses. *PloS pathogens* **13**, e1006258, https://doi.org/10.1371/journal.ppat.1006258 (2017).
28. Friedrich, B. M., Beasley, D. W. C. & Rudra, J. S. Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus. *Vaccine* **34**, 5479–5482, https://doi.org/10.1016/j.vaccine.2016.09.044 (2016).

**Acknowledgements**
T.K. was supported by in part by a JSPS Postdoctoral Fellowship for Research Abroad. D.E.A and L.-F.W’s research is supported by the Singapore Ministry of Health’s National Medical Research Council under its Zika Response Research Fund (NMRC/ZRRF/0002/2016). P.-Y.S. lab was supported by University of Texas Medical Branch (UTMB) startup award, University of Texas STARs Award, CDC grant for the Western Gulf Center of Excellence for Vector-Borne Diseases, Pan American Health Organization grant SCON2016-01353, and UTMB CTSA UL1TR-001439. Sera from WNV-infected mice were generated on studies funded by the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation.

**Author Contributions**
T.K., S.H. and N.B. conducted *in vitro* experiments. D.E.A, L.-F.W., S.L.R., J.N.S., C.S., P.-Y.S., D.W.B and V.V.M. performed *in vivo* study. T.K., V.V. and S.P. conceptualized the study. The original draft was written by T.K. T.K., V.V., D.W.B., C.H., V.V.M. and S.P. edited the manuscript.

**Additional Information**
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-20185-8.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018